Your browser doesn't support javascript.
loading
The stage-dependent prognostic role of ARID1A in hepatocellular carcinoma.
Zhou, Hai; Sun, Dantong; Miao, Chunxiao; Tao, Junyan; Ge, Chao; Chen, Taoyang; Li, Hong; Hou, Helei.
Afiliación
  • Zhou H; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Sun D; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Miao C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Tao J; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Ge C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen T; Qidong Liver Cancer Institute, Qidong, China.
  • Li H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Hou H; Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Transl Cancer Res ; 12(11): 3088-3104, 2023 Nov 30.
Article en En | MEDLINE | ID: mdl-38130310
ABSTRACT

Background:

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death. Although novel treatment currently achieves a better response, the majority of HCC patients develop resistance and cannot benefit. Hence, novel biomarkers for guiding therapy and predicting the prognosis are needed.

Methods:

Tissue microarrays of 206 HCC patients were used, and ARID1A expression was determined by immunohistochemistry. Databases were used for the verification and expansion of our results. The "rms" package of R software was used for the construction of the nomogram.

Results:

ARID family alterations were associated with disease-free survival (P=0.0325) and overall survival (OS) (P=0.0076). Subgroup analysis confirmed the prognostic effect of ARID1A, ARID1B, and ARID2 alterations. In addition, ARID family genomic alterations, especially ARID1A, were closely related to poor progression-free survival (ARID P=0.0011; ARID1A P=0.0082) and OS (ARID P=0.0161; ARID1A P=0.0220) after sorafenib treatment. ARID1A expression was found to display a stage-dependent effect on the prognosis, serving as a risk factor in stage I-II patients (P<0.0001) and a protective factor in stage III-IV patients (P=0.0180).

Conclusions:

ARID1A has dual roles in HCC in a tumor stage-dependent manner, and further study is required to uncover the complex function of ARID1A in HCC development, disease progression, and therapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transl Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China